BUSINESS
Apollo Hospital: Profitability of non-hospital businesses remains a key concern
A credible profitability roadmap for pharmacy is the ask. Although AHEL has the potential to leverage its presence across the entire spectrum of hospitals, pharmacy, and diagnostics, we remain cautious
BUSINESS
PI Industries: Solid execution despite sectoral woes
The company, with superior execution and a solid business model, is on track to achieve its long-term strategic objectives
BUSINESS
Max Healthcare: We are trimming our optimism
Expansion plan supports growth momentum. However, valuations have turned quite high
BUSINESS
Paradeep Phosphate: A long-term opportunity in fertiliser space
FY24/25 to gain from cost efficiencies and improved capacity for this fertiliser player
BUSINESS
Concord Biotech IPO: A differentiated API portfolio to play the China+1 opportunity
The business warrants attention due to superior financials, barriers to entry, and significant market share for key molecules
BUSINESS
UPL: Near-term outlook clouded
Improvement in industry dynamics and continued efforts to reduce debt level will be key to growth
BUSINESS
Coromandel International Q1FY24: Twinkled amidst challenging times
Emerging business segments hold good potential and are likely to be value-accretive.
BUSINESS
Yatharth Hospitals IPO: Wait for a more differentiated business model to emerge
The bulk of the business comes from the NCR region, which is a crowded market for hospitals. Hence, investors looking for long-term gains should wait
BUSINESS
Rallis India: Long-term story in place despite near-term headwinds
We see an improvement in Rallis’ business in FY24-25 and view the current valuation as an opportunity for long-term gains.
BUSINESS
KIMS: A structural growth story with well-oiled levers
KIMS is well-positioned to seize the growing demand for healthcare facilities in the country.
BUSINESS
Sumitomo Chemical India: This stock presents an opportunity for you. How?
It is a company with a healthy balance sheet, R&D-focused parentage and has a huge growth opportunity in the exports market
BUSINESS
Paradeep Phosphate: Benefits of backward integration to kick in
Fertiliser firm to gain from cost efficiencies and improved capacity in FY24/25
BUSINESS
Apollo Hospital: Wait until the fog clears
A credible profitability roadmap for pharmacy is the ask
BUSINESS
Krsnaa Diagnostics: What is strengthening the investment thesis?
The company has a solid and differentiated business model, with promising growth potential
BUSINESS
PI Industries: Volume-led growth to continue for this richly-valued stock
The company, with superior execution and solid business model, is on track to achieve its long-term strategic objectives
BUSINESS
Why Max Healthcare is our preferred pick?
Aggressive expansion plan supports growth momentum
BUSINESS
Coromandel International: Multiple growth opportunities at work
Emerging business segments hold good potential and are likely to be value accretive
BUSINESS
Sharda Cropchem: A good quarter and a firm outlook
Near-term positive outlook and attractive valuations create room for a stock upside
BUSINESS
A dismal fourth quarter for UPL
Improvement in industry dynamics and continued efforts to reduce debt level will be key to growth
BUSINESS
PI Industries: Foray into high-margin pharma CDMO business adds to our conviction
CDMO is a robust and fast-growing market. These acquisitions will diversify PI’s business model
BUSINESS
Why PI Industries is a preferred pick in the agrochemical space
The acquisitions in the pharma API and intermediates business will be earnings and value-accretive.
BUSINESS
Rallis India: Facing a double whammy in the short term
We see an improvement in Rallis’ business in FY24 and view the recent correction as an opportunity for long-term gains
BUSINESS
Mankind Pharma IPO: A pricey proposition on branded domestic pharma market
As the company is foraying into newer areas of therapies, particularly chronic, there could be execution hiccups.
BUSINESS
Diagnostics: Time to look at this quasi-consumer industry
A bigger landscape of opportunity awaits organised diagnostic chains to increase market share
